

# Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers

NCT07396376

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Eluciderm Inc
Enrollment	15 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- Age 18 to 75 years;
- Diagnosis of type 1 or type 2 diabetes mellitus;
- A1C  $\leq$  10 (historical within 2 months accepted);
- BMI  $\leq$  36;
- Index DFU Wagner grade 1-2 with post debridement area  $\leq$  1.0 cm<sup>2</sup> and  $\leq$  8.0 cm<sup>2</sup>;
- ... and 5 more (see full listing online)

### Exclusion (10)

- Infected index ulcer or surrounding cellulitis;
- Ischemic ulcers; osteomyelitis or exposed bone;
- Recent systemic antibiotic requirement for active infection (eligibility after resolution and 7 day washout);
- Acute/inactive Charcot preventing off loading; hemoglobin  $<$  10 g/dL (unless Sponsor approves);
- ESRD requiring dialysis;
- ... and 5 more (see full listing online)

## Locations (4 total)

---

Gateway Clinical Trials, O'Fallon, Illinois, United States  
Independent Clinical Research LLC, Springfield, Illinois, United States  
Curalta Clinical Trials, Oradell, New Jersey, United States  
... and 1 more locations